Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhinitis,Allergic Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome

NCT01461200
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Swab of vestibule and middle meatus of nose
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

NCT00987233
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
triamcinolone acetonide aqueous nasal spray (Apotex Inc.), triamcinolone acetonide aqueous nasal spray (Nasacort® AQ), Placebo
Drug
Lead sponsor
Apotex Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Sep 21, 2026, 11:24 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity

NCT00584051
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 21, 2026, 11:24 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

NCT01989897
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol
Drug
Lead sponsor
Bryan Martin, DO
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00609674
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

NCT00772304
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine 0.6% / Azelastine 137 mcg
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
29
States / cities
Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients

NCT01179282
View directory record Official record
Conditions
ALLERGIC RHINITIS
Interventions
dust mite extract or placebo
Biological
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00435461
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate and fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 21, 2026, 11:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

NCT04981717
View directory record Official record
Conditions
Allergic Rhinitis Due to Cat Allergy
Interventions
REGN1908-1909, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Adults Sensitized to Cat

NCT00689299
View directory record Official record
Conditions
Allergy
Interventions
Standardized Allergenic Extract, Cat Hair, Placebo
Biological
Lead sponsor
Antigen Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Marietta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

NCT00829985
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Asthma
Interventions
Glycerinated German Cockroach Allergenic Extract, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

NCT01439815
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Fluticasone Propionate Nasal Spray, Saline Nasal Spray
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

NCT00621959
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

NCT02696850
View directory record Official record
Conditions
Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions
Budesonide, Saline alone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

NCT01915823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride and fluticasone propionate, Dymista vehicle
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 21, 2026, 11:24 PM EDT
Terminated Phase 1 Interventional

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

NCT00630461
View directory record Official record
Conditions
Mild Allergic Rhinitis, Mild Allergic Rhinitis With Mild Asthma
Interventions
Clinical Center Reference Endotoxin
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects

NCT01171664
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, STAHIST
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
South Bend, Indiana • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

NCT00078195
View directory record Official record
Conditions
Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions
omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00502775
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
fluticasone furoate, fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
42
States / cities
Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 21, 2026, 11:24 PM EDT